Gateways to clinical trials

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 29, Issue 3, 2007, Pages 231-245

  Bayes M ^a   Rabasseda, X ^a   Prous, J R ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN; ALVIMOPAN; AMBRISENTAN; ANTIVITAMIN K; AXITINIB; CANNABIDIOL; DAPOXETINE; DELAPRIL; DESVENLAFAXINE; DIGOXIN; DRONABINOL; DRONEDARONE; ENOXAPARIN; FUMARIC ACID DIMETHYL ESTER; GEMCITABINE; HYALURONIC ACID; HYDROCHLOROTHIAZIDE; LAPATINIB; MANIDIPINE; OLMESARTAN; PERTUZUMAB; PEXELIZUMAB; PIRFENIDONE; PLACEBO; RAMIPRIL; RIVAROXABAN; SEMAXANIB; TETRAPLATIN; UNINDEXED DRUG; VILDAGLIPTIN;

CLINICAL RESEARCH; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DEPRESSION; DIABETES MELLITUS; DRUG DOSE TITRATION; DRUG EFFECT; DRUG TOLERABILITY; HEAD AND NECK CANCER; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; LUNG SMALL CELL CANCER; MULTIPLE SCLEROSIS; NEUROFIBROMA; OBESITY; OSTEOARTHRITIS; PRACTICE GUIDELINE; PROSTATE CANCER; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; REVIEW; SALIVARY GLAND CANCER; THYROID CANCER;

CLINICAL TRIALS; HUMANS;

EID: 34250312843     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (87)

1. Davy, J.M., Herold, M., Hoglund, C., Radzik, D., Timmermans, A.J.M. Effect of dronedarone on exercise in patients with permanent atrial fibrillation. Eur Heart J 2006, 27(Abstract Suppl.): Abst P5154.
2. Givertz, M.M., Tansey, M., Pearson, L.L., Fields, T.K., Dittrich, H.C. Effect of the adenosine A1 receptor antagonist. KW-3902. on diuresis and renal function in patients with acute decompensated heart failure refractory to maximum doses of conventional diuretics: A randomized, double-blind, placebo controlled, dose escalation study. Circulation 2006, 114(18, Suppl. 2): Abst 2164.
3. Armstrong, P.W., Granger, C.B., Adams, P.X. et al. Pexelizumab for acute ST-elevation myocardial infarction in patients under-going primary percutaneous coronary intervention. JAMA 2007, 297(1): 43.
4. Dittrich, H.C., Gupta, D., Dowling, T., Tansey, M., Callahan, J.D., Thompson, S. The effect of KW-3902. an adenosine A1 receptor antagonist, on renal function and renal plasma flow in subjects with heart failure and renal impairment: A randomized, double-blind, placebo-controlled, two-way crossover study. Circulation 2006, 114(18, Suppl. 2): Abst 2731.
5. Cuchel, M., Bloedon, T.L., Szapary, O.P. et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med 2007, 356(2): 148.
6. Husted, S., Emanuelsson, H., Heptinstall, S., Sandset, P.M., Wickens, M., Peters, G. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: A double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006, 27(9): 1038.
7. Kilo, C. et al. Aliskiren, a novel renin inhibitor for treatment of hypertension, enhances renin system suppression by reducing plasma renin activity alone or in combination with ramipril in patients with diabetes. Eur Heart J 2006, 27(Abstract Suppl.): Abst P789.
8. Sica, D., Gradman, A., Lederballe, O., Meyers, M., Cai, J. Aliskiren, a novel renin inhibitor, is well tolerated and has sustained BP-lowering effects alone or in combination with HCTZ during long-term (52 weeks) treatment of hypertension. Eur Heart J 2006, 27(Abstract Suppl.): Abst P797.
9. Mugellini, A., Lazzari, P., Zoppi, A. et al. Effect of delapril manidipine combination vs olmesartan hydrochlorothiazide combination on insulin sensitivity in obese hypertensive patients. J Hypertens 2006, 24(Suppl. 4): Abst P12.222.
10. Galie, N., Olschewsky, H., Ghofrani, H.A. et al. Ambrisentan improves 6-minute walk distance and decreases brain natriuretic peptide in patients with pulmonary arterial hypertension. Eur Heart J 2006, 27(Abstract Suppl.): Abst 4875.
11. Agnelli, G. et al. Treatment of acute, symptomatic, proximal deep vein thrombosis with the oral, direct factor Xa inhibitor rivaroxaban (BAY 59-7939) - the ODIXa-DVT dose-ranging study. Eur Heart J 2006, 27(Abstract Suppl.): Abst P4569.
12. Kelleher, D., Johanson, J., Pobiner, B., Carter, E., Dukes, G. Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist - A study in patients with chronic idiopathic constipation (CIC) not taking opioid medication. Am J Gastroenterol 2006, 101(Suppl. 2): Abst 1239.
13. Cohen, L.B., Wang, C., Jones, J.B. Physician and patient satisfaction for Aquavan in a randomized, double-blind, multicenter, dose-finding colonoscopy study. Am J Gastroenterol 2006, 101 (Suppl. 2): Abst 1342.
14. Cohen, L.B., Kline, J., Wang, C., Jones, J.B. Aquavan for moderate sedation during colonoscopy: Results of a phase 2, multi-center, randomized, dose-response study. Am J Gastroenterol 2006, 101(Suppl. 2): Abst 1343.
15. Jones, J., Wang, C. Fospropofol disodium for moderate sedation during colonoscopy produces clear-headed recovery. Am J Gastroenterol 2006, 101(Suppl. 2): Abst 1026.
16. Weinstein, M.L., Wang, C., Jones, J. Safety and efficacy of fospropofol disodium versus midazolam hydrochloride for sedation in elderly patients undergoing colonoscopy. Am J Gastroenterol 2006, 101(Suppl. 2): Abst 1313.
17. Leslie, J., Steinbrook, R., Viscusi, E., Du, W., Techner, L. Alvimopan oral dosing 30-90 minutes before and BID after bowel resection accelerates G1 recovery. Anesthesiology 2006, 105(Suppl.): Abst A122.
18. Benson, M.D., Dember, L.M., Gorevic, P.D. et al. Beneficial effects of eprodisate (NC-503) for patients with amyloid A (AA) amyloidosis: Results of a 2-year, multi-center, randomized, placebo-controlled trial. Am J Gastroenterol 2006, 101(Suppl. 2): Abst 1168.
19. He, Y.L., Horowitz, A., Watson, C.E. et al. Vildagliptin does not affect C-Peptide clearance in patients with type 2 diabetes. J Clin Pharmacol 2007, 47(1): 127.
20. Ekberg, K., Brismar, T., Johansson, B.L. et al. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy. Diabetes Care 2007, 30(1): 71.
21. Merriam, G.R., Blackman, M.R., Hoffman, A.R. et al. Effects of chronic treatment with an oral growth hormone (GH) secretogogue on nocturnal GH and IGF-1 in older men and women. Front Neuroendocrinol 2006, 27(1): Abst.
22. Lee, J.H., Chan, J.L., Sourlas, E., Raptopoulos, V., Mantzoros, C.S. Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy. J Clin Endocrinol Metab 2006, 91(7): 2605.
23. Bruehlmann, P. Overall tolerability and analgesic activity of sinovial in the treatment of knee OA. Osteoporos Int 2006, 17(Suppl. 1): Abst SY433.
24. Ostergaard, M., Wiell, C., Sierakowski, S. et al. HuMax-CD20, a novel fully human monoclonal IgG1 antibody in the treatment of rheumatoid arthritis. Arthritis Rheum 2006, 54(9, Suppl.): Abst 2122.
25. Depont, F., Addra, I., Lechevallier, N. et al. Efficacy and tolerability of hyaluronic acid visco-supplementation with Sinovial for the treatment of knee osteoarthritis: A retrospective observational study. Osteoporos Int 2006, 17(Suppl. 1):Abst P363.
26. Gordon, M.S., Eder, J.P., Mendelson, D.S. et al. CBP501, a novel cell cycle G2 checkpoint abrogator. Preliminary results of the initial phase I and pharmacokinetic (PK)/pharmacodynamic (PD) study in patients (pts) with advanced solid tumors. Eur J Cancer Suppl 2006, 4(12): Abst 346.
27. Lorusso, P.M., Heath, E., Valdivieso, M. et al. Phase I evaluation of AZD2171, a highly potent and selective inhibitor of VEGFR signaling, in combination with selected chemotherapy regimens inpatients with advanced solid tumors. J Clin Oncol 2006, 24(18, Suppl.): Abst 3034.
28. Protheroe, A., Reid, A., Attard, G, et al. A phase I dose finding study of the aminopeptidase inhibitor CHR-2797 in patients with treatment refractory metastatic cancer. Ann Oncol 2006, 17 (Suppl. 9): Abst 412P.
29. LoRusso, P., Heath, E., Malburg, L. et al. Phase I multi-cohort study evaluating the safety and tolerability of AZD2171 in combination with various anticancer regimens. Ann Oncol 2006, 17 (Suppl. 9): Abst 405P.
30. Carducci, M., Siu, L.L., Sullivan, R. et al. Phase I study of iso-type-selectivc histone deacetylase (HDAC) inhibitor MGCD0103 given as three-times weekly oral dose in patients (pts) with advanced solid tumors. J Clin Oncol 2006, 24(18, Suppl.): Abst 3007.
31. Yamada, K., Yamamoto, N., Fujiwara, Y. et al. Phase I study of HER-2 targeted RhuMAb 2C4 (pertuzumab) in Japanese patients with solid tumors. Ann Oncol 2006, 17(Suppl. 9): Abst 435.
32. Fury, M.G., Zahalsky, A., Wong, R. et al. A Phase II study of SU5416 in patients with advanced or recurrent head and neck cancers. Invest New Drugs 2007, 25(2): 165.
33. Alousi, A.M., Boinpally, R., Wiegand, R. et al. A phase I trial of XK469: Toxicity profile of a selective topoisomerase IIbeta inhibitor. Invest New Drugs 2007, 25(2): 147.
34. Van der Heijden, A.G. et al. Phase II marker lesion study with intravesical instillation of eoquin in superficial bladder cancer: Toxicity, marker response and follow up. Urology 2006, 68 (Suppl. 5A): Abst PD-11.11.
35. Estève, M.A., Devictor-Pierre, B., Galy, G. et al. Severe acute toxicity associated with high-dose methotrexate (MTX) therapy: Use of therapeutic drug monitoring and test-dose to guide carboxypeptidase G2 rescue and MTX continuation. Eur J Clin Pharmacol 2007, 63(1): 39.
36. Burstein, H.J., Overmoyer, B., Gelman, R. et al. Rebeccamycin analog for refractory breast cancer: A randomized phase II trial of dosing schedules. Invest New Drugs 2007, 25(2): 161.
37. Cameron, D.A., Geyer, C.E., Chan, D.S. et al. Lapatinib in combination with capecitabine demonstrates superior efficacy compared with capecitabine alone in ERBB2+ advanced or metastatic breast cancer (MBC) patients (PTS) pretreated with chemotherapy and trastuzumab. Ann Oncol 2006, 17(Suppl. 9): Abst 141O.
38. Trudeau, M., Johnston, S., Kaufman, B. et al. Lapatinib (Tycerb) monotherapy in patients (PTS) with recurrent inflammatory breast cancer (IBC): Clinical activity and biologic predictors of response. Ann Oncol 2006, 17(Suppl. 9): Abst 140O.
39. Heras, V., Hatzopoulos, A., Heras, P. Liposome-encapsulated doxorubicin plus cyclophosphamide as first-line therapy in metastatic breast cancer. Ann Oncol 2006, 17(Suppl. 9): Abst 196.
40. Pivot, X., Thomas, E., Lerzo, G. et al. Ixabepilone in patients (PTS) with metastatic breast cancer (MBC) that is resistant to an anthracycline, a taxane and capecitabine. Ann Oncol 2006, 17 (Suppl. 9): Abst 145PD.
41. Savarese, A., Vizza, E., Felici, A. et al. Cisplatin, paclitaxel and ifosfamide as a two-days neoadjuvant chemotherapy in bulky/locally advanced cervical carcinoma. Ann Oncol 2006, 17(Suppl. 9): Abst 5420.
42. Jonker, D., Cripps, C., Gauthier, I. et al. Phase I study of AZD21Z1 in combination with capecitabine (CAPE) in patients with advanced colorectal cancer (CRC). Ann Oncol 2006, 17 (Suppl. 9): Abst 355P.
43. Trarbach, T., Major, P., Lenz, H.J. et al. A meta-analysis of two randomized, double-blind, placebo-controlled, phase III studies in patients (pts) with metastatic colorectal cancer (MCRC) receiving FOLFOX4 and PTK/ZK to determine clinical benefit on progression-free survival (PFS) in high LDH pts. Ann Oncol 2006, 17 (Suppl. 9): Abst 352P.
44. Koehne, C.-H., Bajetta, E., Lin, E. et al. Results of an interim analysis of a multinational randomized, double-blind, phase III study in patients (pts) with previously treated metastatic colorectal cancer (MCRC) receiving FOLFOX4 and (PTK787/ZK) or placebo (CONFIRM 2). Ann Oncol 2006, 17(Suppl. 9): Abst 351P.
45. Hawkins, R.E., Ravaud, A., Von der Masse, H. et al. Lapatinib extends survival in patients (pts) with high ErbB1 (EGFR) tumour expression: Subgroup results of a phase III trial in advanced renal cell carcinoma (RCC). Ann Oncol 2006, 17(Suppl. 9): Abst 440O.
46. Winquist, E., Knox, J., Ayoub, J.-P. et al. Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: A National Cancer Institute of Canada Clinical Trials Group investigational new drug study. Invest New Drugs 2006, 24(2): 159.
47. Macias, A.E. Compassionate study use of IE10/aluminum anti-idiotype vaccine in patients with advanced non-small-cell lung cancer (NSCLC): Preliminary report. Ann Oncol 2006, 17(Suppl. 9): Abst 414P.
48. Shawler, D.L., Nemunaitis, J., Dillman, R.O. et al. Phase II stufy of a TGF-beta2 antisense gene-modified allogeneic tumor cell vaccine for non-small cell lung cancer. Proc Am Assoc Cancer Res (AACR) 2006, 47: Abst LB-236.
49. Millest, A. et al. ZD6474 (Zactima), an orally available inhibitor of key signalling pathways in cancer. Ann Oncol 2006, 17(Suppl. 9): Abst 790P.
50. Hensing, T.A., Hanna, N.H., Gillenwater, H.H., Camboni, M.G., Allievi, C., Socinski, M.A. Phase II study of BBR 3464 as treatment in patients with sensitive or refractory small cell lung cancer. Anti-Cancer Drugs 2006, 17(6): 697.
51. Spano, J.P., Moore, M., Kim, S. et al. A phase I study of axitinib (AG-013736), a potent inhibitor of VEGFRs, in combination with gemcitabine (GEM) in patients (pts) with advanced pancreatic cancer. J Clin Oncol 2006, 24(18, Suppl.): Abst 13092.
52. Iversen, P. et al. Determining the optimal initiation and maintenance dose of degarelix for hormone therapy of prostate cancer patients. Urology 2006, 68(Suppl. 5A): Abst MP-08.18.
53. Attard, G., Bellmunt, J., De Bono, J.S. et al. An open label phase II study to evaluate the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naïve patients with hormone refractory prostate cancer. Ann Oncol 2006, 17(Suppl. 9): Abst 445PD.
54. Fong, L. et al. A phase I trial of combination immunotherapy with CTLA-4 blockade and GM-CSF in hormone-refractory prostate cancer. J Clin Oncol 2006, 24(18, Suppl.): Abst 2508.
55. Agulnik, M., Cohen, E.E., Cohen, R.B. et al. A multicenter phase II study of lapatinib in recurrent or metastatic adenoid cystic (ACC) and non-ACC malignant tumors of the salivary glands (MSGT). Ann Oncol 2006, 17(Suppl. 9): Abst 572O.
56. Ryan, C.W., Dolan, M.E., Brockstein, B.B. et al. A phase II trial of O(6)-benzylguanine and carmustine in patients with advanced soft tissue sarcoma. Cancer Chemother Pharmacol 2006, 58(5): 634.
57. Cohen, E.E., Vokes, E.E., Rosen, L. et al. A phase 2 study of axitinib (AG-013736), a potent inhibitor of VEGFRS, in patients with advanced thyroid cancer. Ann Oncol 2006, 17(Suppl. 9): Abst 579PD.
58. Blum, W., Cheng, H., Grever, M. et al. Population pharmacokinetics (PK) of GTI-2040 in patients with acute myeloid leukemia (AML). AAPS J 2006, 8 (Suppl. 1): Abst W4398.
59. Knapper, S., Burnett, A.K., Littlewood, T. et al. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood 2006, 108(10): 3262.
60. O'Connor, O. et al. Early phase experience with pralatrexate (10-propargyl-10-deazaaminopterin [PRX]), a novel antifolate with high affinity for the reduced folate carrier, in patients with chemotherapy refractory lymphoproliferative malignancies. Eur J Cancer Suppl 2006, 4(12): Abst 461.
61. KRX-0401 studied with Revlimid and dexamethasone for multiple myeloma. DailyDrugNews.com (Daily Essentials) 2007.
62. Yee, K.W., Cortes, J., Ferrajoli, A. et al. Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome. Leuk Res 2006, 30(7): 813.
63. Karp, J.E., Rizzieri, D., Vey, N. et al. Cloretazine is an effective induction therapy in elderly patients (pts) with poor-risk de novo AML. J Clin Oncol 2006, 24(18, Suppl.): Abst 6512.
64. Babovic-Vuksanovic, D., Ballman, K., Michels, V. et al. Phase II trial of pirfenidone in adults with neurofibromatosis type 1. Neurology 2006, 67(10): 1860.
65. Tamches, E., Orgogozo, J.-M., Wilkinson, D. et al. ZT-1 for the symptomatic treatment of mild to moderate Alzheimer disease (AD): Preliminary results of a multicenter, randomised, double-blind, placebo and active controlled phase II study. Alzheimer Dement 2006, 2(3, Suppl. 1): Abst P4-366.
66. Kappos, L., Miller, D.H., MacManus, D.G. et al. BG00012, a novel oral fumarate, is effective in patients with relapsing-remitting multiple sclerosis. Multiple Scler 2006, 12(1, Suppl.): Abst P325.
67. Collin, C., Ambler, Z., Kent, R., McCalla, R. A randomised controlled study of Sativex(R) in patients with symptoms of spasticity due to multiple sclerosis. Multiple Scler 2006, 12(1, Suppl.): Abst P412.
68. McPhee, S.W., Janson, C.G., Li, C. et al. Immune responses to AAV in a phase I study for Canavan disease. J Gene Med 2006, 8(5): 577.
69. DeMartinis, N., Yeung, P.P., Entsuah, R., Manley, A.L. Randomized, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder. Int J Neuropsychopharmacol 2006, 9(Suppl. 1): Abst P03.021.
70. Septien-Velez, L., Pitrosky, B., Padmanabhan, S.K., Germain, J.M. Efficacy and safety of desvenlafaxine succinate in the short-term treatment of major depressive disorder in adults. Int J Neuropsychopharmacol 2006, 9(Suppl. 1): Abst P03.022.
71. Septien-Velez, L., Pitrosky, B., Padmanabhan, S.K., Germain, J.M. Treating pain in patients with major depressive disorder: Efficacy of desvenlafaxine succinate, a new serotonin and norepinephrine reuptake inhibitor. Int J Neuropsychopharmacol 2006, 9 (Suppl. 1): Abst P01.134.
72. Kennedy, S.H., Olie, J.P., Loo, H., Emsley, R. Efficacy ofagomelatine 25-50 mg in major depressive disorder. Int J Neuropsychopharmacol 2006, 9(Suppl. 1): Abst P03.013.
73. Pryor, J.L., Althof, S.E., Steidle, C. et al. Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: An integrated analysis of two double-blind, randomised controlled trials. Lancet 2006, 368(9539): 929.
74. Creinin, M.D., Schlaff, W., Archer, D.F. et al. Progesterone receptor modulator for emergency contraception: A randomized controlled trial. Obstet Gynecol 2006, 108(5): 1089.
75. Dieterich, H., Kemp, C., Vaidyanathan, S., Yeh, C. Aliskiren, the first in a new class of orally effective renin inhibitors, has no clinically significant drug interactions with digoxin in healthy volunteers. Clin Pharmacol Ther 2006, 79(2): Abst PIII-24.
76. Stoute, J.A., Gombe, J., Withers, M.R. et al. Phase I randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya. Vaccine 2007, 25(1): 176.
77. Frey, S.E., Gorse, G.J., DiBisceglie, A.M. et al. A phase I trial of a novel E1E2/MF59C.I hepatitis C vaccine candidate in healthy HCV-negative adults (DMID 01-002). J Clin Virol 2006, 36 (Suppl. 2): Abst O015.
78. Van Dorp, E., Sarton, E., Dahan, A. Morphine-6-glucuronide is analgesic in electrical pain model but hyperalgesic in heat pain model. Anesthesiology 2006, 105(Suppl.): Abst A495.
79. Almeida, L., Falcao, A., Vaz-da-Silva, M. et al. Effect of single-doses of nebicapone (BIA 3-202) on the catechol-O-methyltransferase (COMT) activity in healthy subjects. Mov Disord 2006, 21 (Suppl. 15): Abst PI 128.
80. Qadri, F., Chowdhury, M.I., Faruque, S.M. et al. Peru-15, a live attenuated oral cholera vaccine, is safe and immunogenic in Bangladeshi toddlers and infants. Vaccine 2007, 25(2): 231.
81. Brandt, J.T., Payne, C.D., Wiviott, S.D. et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: Magnitude of platelet inhibition is related to active metabolite formation. Am Heart J 2007, 153(1): 66.e9.
82. Mielcarz, G., Howard. A.N., Barinow-Wojewodzki, A. Supplementation with quercetin and non-alcoholic red wine extract increase fibrinolytic factor T-PA activity and anti-inflammatory cytokine TGF-beta1. Atherosclerosis Suppl 2006, 7(3): Abst We-P14: 426.
83. Hemmeter, U.M., Thum, A., Giesler, M. et al. Effects of a phytopharmacal triple combination of St. John's wort, valerian and passion flower on sleep EEG, cognitive performance and mood: A double-blind randomised cross-over study in healthy volunteers. Eur Neuropsychopharmacol 2006, 16(Suppl. 4): S318.
84. Franklin, M., Hafizi, S., Murck, H., Hockney, R., Reed, A. Effect of sub-chronic treatment with Jarsin (extract of St John's wort, Hypericum perforatum) at two dose levels on evening salivary melatonin and Cortisol in healthy male volunteers. Int J Neuropsychopharmacol 2006, 9 (Suppl. 1): Abst P03.113.
85. Peters, G. et al. Multiple dose pharmacokinetics (PK) and pharmacodynamics (PD) of the reversible oral ADP receptor antagonist AZD6140. Eur Heart J 2006, 27(Abstract Suppl.): Abst P4556.
86. Shibayama, T., Matsushita, Y., Hirota, T., Ikeda, T., Kuwahara, S. Pharmacokinetics of CS-023 (RO4908463), a novel parenteral carbapenem, in healthy male Caucasian volunteers. Antimicrob Agents Chemother 2006, 50(12): 4186.
87. Porchet, H., Scalfaro, P., Aeschlimann, C. et al. The prolonged action of the acetylcholinesterase inhibitor ZT-1 after subcutaneous injections of sustained release implants in healthy volunteers. Alzheimer Dement 2006, 2(3, Suppl. 1): Abst P4-368.